FEDERAL COURT OF AUSTRALIA
Pfizer Inc v Commissioner of Patents [2005] FCA 137
PATENT – application for extension of term – appeal from decision of the Deputy Commissioner of Patents refusing the extension – construction of s 70(2)(a) of the Patents Act1990 (Cth) – whether disclosure and description of a generic formula was an “in substance” disclosure of the compound within that formula – whether there was “real and reasonably clear disclosure” – where there is “real and reasonably clear disclosure” there is also “in substance” disclosure – the existence of a later selection patent is not relevant to whether there is “in substance” disclosure for the purposes of an application for extension of term under s 70(2)(a) – application remitted to the Commissioner
WORDS AND PHRASES – “must in substance be disclosed” – “in substance”
Administrative Decisions (Judicial Review) Act 1977 (Cth)
Patents Act 1990 (Cth)AMP Incorporated v Commissioner of Patents (1974) AOJP 3224
CCOM Pty Ltd v Jiejing Pty Ltd (1994) 51 FCR 260
Coopers Animal Health Australia Ltd v Western Stock Distributors Pty Ltd (1987) 15 FCR 382
Ethyl Corporation's Patent [1972] RPC 169
F. Hoffman-La Roche v Commissioner of Patents (1971) 123 CLR 529
Gambro Pty Ltd v Fresenius Medical Care South East Asia Pty Ltd (2000) 49 IPR 321
ICI Chemicals & Polymers Ltd v Lubrizol Corp (1999) AIPC 91 91-521
Imperial Chemical Industries Pty Ltd v Commissioner of Patents [2004] FCA (1658)
Institut Francais du Petrole des Carburants et Lubricants’ Application [1972] FSR 147
Lockwood Security Products Pty Ltd v Doric Products Pty Ltd (2004) 2121 ALR 1
Merck & Co Inc v Sankyo Co Ltd (1992) 23 IPR 415
Prestige Group (Australia) Pty Ltd v Dart Industries Inc (1990) 26 FCR 197
Re ICI Chemicals & Polymers Ltd v The Lubrizol Corporation Inc (2000) 106 FCR 214
Re IG Farbenindustries Patents (1930) 47 RPC 289
RGC Mineral Sands Pty Ltd v Wimmera Industrial Minerals Pty Ltd (1998) 89 FCR 458
Societe Des Usines Chemiques Rhone-Poulenc v Commissioner of Patents (1959) 100 CLR 5
University of Georgia Research Foundation v Biochem Pharma Inc (2000) 51 IPR 222TA Blanco White, Patents for Inventions, 4th ed., Stevens & Sons, London, 1974
PFIZER INC v COMMISSIONER OF PATENTS
NSD1024 OF 2004
BENNETT J
1 MARCH 2005
SYDNEY
IN THE FEDERAL COURT OF AUSTRALIA
NEW SOUTH WALES DISTRICT REGISTRY
NSD1024 OF 2004
BETWEEN:
PFIZER INC
APPLICANTAND:
COMMISSIONER OF PATENTS
RESPONDENTJUDGE:
BENNETT J
DATE OF ORDER:
1 MARCH 2005
WHERE MADE:
SYDNEY
THE COURT ORDERS THAT:
1.The decision of the Deputy Commissioner of Patents made on 4 June 2004 be set aside with effect from 4 June 2004.
2.The matter be remitted to the Commissioner of Patents for determination according to law.
Note: Settlement and entry of orders is dealt with in Order 36 of the Federal Court Rules.
IN THE FEDERAL COURT OF AUSTRALIA
NEW SOUTH WALES DISTRICT REGISTRY
NSD1024 OF 2004
BETWEEN:
PFIZER INC
APPLICANTAND:
COMMISSIONER OF PATENTS
RESPONDENT
JUDGE:
Keep reading for free
Create a free CaseChat account to read Pfizer Inc v Commissioner of Patents and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2005] FCA 137
- Decision Date
CaseChat Overview and Summary
Orders
Orders of the court
1. The decision of the Deputy Commissioner of Patents made on 4 June 2004 be set aside with effect from 4 June 2004.
2. The matter be remitted to the Commissioner of Patents for determination according to law.
Background
Background to the litigation
Evidence
Evidence Before The Court
Decision
Reasons for decision
Ratio Decidendi
Legal Principle Established
Established by: BENNETT J
Mr Catterns submits that the words “in substance” do not import a lesser test of meaning “it’s nearly there” but rather looks to the question as a matter of substance or quality.CONSIDERATIONIs the selection patent relevant to the question of the construction of the parent patent? Section 70(2)(a) is in Chapter 6, Part 3 of the Act entitled ‘Extension of term of standard patents relating to pharmaceutical substances’. There is nothing in the section that requires examination of the validity of the patent sought to be extended. It is a question of whether s 70(2)(a) is satisfied. It is accepted that voriconazole falls within the scope of the claims, so the question is whether voriconazole is in substance disclosed in the specification. This requires examination of the specification itself. On 18 November 2004, the High Court delivered its judgment in Lockwood Security Products Pty Ltd v Doric Products Pty Ltd (2004) 2121 ALR 1 (‘Doric’), after the hearing of this matter had concluded. The High Court made it clear that, in considering fair basis, an examination of the specification goes to the form that the specification takes (at [44]). There is no reason to introduce “inventiveness” or “meritoriousness” or inventive step (Doric at [46] and [48] and [53]-[54]). It is a question only of what is said in the specification (Doric at [72]). To the extent that there is any conflict between Doric and the observations of Gibbs J in Roche which were not part of the ratio of that case, clearly Doric is authoritative. The same principles apply to a consideration of “in substance disclosure” in a specification. In effect, the Deputy Commissioner took into account the selection patent in the construction of the parent patent. He considered the alleged new inventive step that resulted in the selection patent to be relevant to the construction of and the disclosures of the parent patent. In my opinion the selection patent, either by reason of its existence or as evidence in the construction of the parent patent for the purpose of ascertaining disclosure within the meaning of s 70(2)(a), was irrelevant. Counsel for both the applicant and the respondent compared the test in s 70(2)(a) with that of fair basis on matter disclosed in priority documents and of fair basis on matter described in the specification. They also discussed concepts of inventiveness and inventive step. It was in that context that the selection patent was taken as evidence of an inventive step. In particular, Mr Catterns submits that, if it takes an inventive step to derive the compound from the bare formula, there can be no real and reasonably clear disclosure of the compound. In support of that proposition, Mr Catterns relies upon Roche at 542-543 and Coopers Animal Health Australia Ltd v Western Stock Distributors Pty Ltd (1987) 15 FCR 382 (‘Coopers’) at 398. As noted by the Deputy Commissioner, Roche is authority for the proposition that a claim to a single compound included in the class of chemical compounds covered by a chemical formula is fairly based (see Roche at 541). The question is whether the ‘caveats’ identified by Gibbs J in that decision are applicable to deprive the single compound of fair basis on the grounds that it was the subject of a claim to a later selection.